Covered recipient · General Payments record
GREGG A MILLER
Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$595,230.00
243 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $595,230.00 | 243 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $401,040.00 | 204 |
| PFIZER INC. | $179,370.00 | 26 |
| MEDIVATION INC. | $14,820.00 | 13 |
Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GREGG A MILLER
NPI 1902820756 · CMS profile ID 1214613
Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology
BOSTON, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902820756?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GREGG A MILLER, NPI 1902820756, CMS profile ID 1214613. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902820756?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). GREGG A MILLER, NPI 1902820756, CMS profile ID 1214613. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902820756?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- GREGG A MILLER, NPI 1902820756, CMS profile ID 1214613, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1902820756?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
243 matching records · $595,230.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 243.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $960.00 | 11/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747843527 | CMS |
| Merck Sharp & Dohme Corporation | $4,740.00 | 11/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747847573 | CMS |
| Merck Sharp & Dohme Corporation | $540.00 | 11/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747847577 | CMS |
| Merck Sharp & Dohme Corporation | $780.00 | 11/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747848665 | CMS |
| Merck Sharp & Dohme Corporation | $2,400.00 | 11/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747851013 | CMS |
| MEDIVATION INC. | $740.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743507509 | CMS |
| Merck Sharp & Dohme Corporation | $140.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747797839 | CMS |
| Merck Sharp & Dohme Corporation | $170.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747797841 | CMS |
| Merck Sharp & Dohme Corporation | $1,840.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747797843 | CMS |
| Merck Sharp & Dohme Corporation | $305.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747797849 | CMS |
| Merck Sharp & Dohme Corporation | $3,500.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747797937 | CMS |
| PFIZER INC. | $6,750.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743497753 | CMS |
| PFIZER INC. | $4,710.00 | 10/12/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743507835 | CMS |
| Merck Sharp & Dohme Corporation | $3,120.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842437 | CMS |
| Merck Sharp & Dohme Corporation | $3,420.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842439 | CMS |
| Merck Sharp & Dohme Corporation | $12,900.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842667 | CMS |
| Merck Sharp & Dohme Corporation | $180.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842779 | CMS |
| Merck Sharp & Dohme Corporation | $185.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842791 | CMS |
| Merck Sharp & Dohme Corporation | $250.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842887 | CMS |
| Merck Sharp & Dohme Corporation | $250.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842889 | CMS |
| Merck Sharp & Dohme Corporation | $3,660.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747842961 | CMS |
| Merck Sharp & Dohme Corporation | $540.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747843065 | CMS |
| Merck Sharp & Dohme Corporation | $90.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747843149 | CMS |
| Merck Sharp & Dohme Corporation | $720.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747843343 | CMS |
| Merck Sharp & Dohme Corporation | $360.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747843445 | CMS |
| Merck Sharp & Dohme Corporation | $360.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747843447 | CMS |
| Merck Sharp & Dohme Corporation | $850.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747847581 | CMS |
| Merck Sharp & Dohme Corporation | $60.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747847817 | CMS |
| Merck Sharp & Dohme Corporation | $1,200.00 | 10/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747851003 | CMS |
| MEDIVATION INC. | $680.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743507831 | CMS |
| Merck Sharp & Dohme Corporation | $1,590.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776335 | CMS |
| Merck Sharp & Dohme Corporation | $1,820.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776337 | CMS |
| Merck Sharp & Dohme Corporation | $2,230.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776423 | CMS |
| Merck Sharp & Dohme Corporation | $90.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776427 | CMS |
| Merck Sharp & Dohme Corporation | $3,280.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776509 | CMS |
| Merck Sharp & Dohme Corporation | $3,340.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776511 | CMS |
| PFIZER INC. | $7,565.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743497745 | CMS |
| PFIZER INC. | $6,000.00 | 09/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743507507 | CMS |
| Merck Sharp & Dohme Corporation | $125.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747802089 | CMS |
| Merck Sharp & Dohme Corporation | $6,060.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747802097 | CMS |
| Merck Sharp & Dohme Corporation | $3,420.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747802149 | CMS |
| Merck Sharp & Dohme Corporation | $4,085.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747802151 | CMS |
| Merck Sharp & Dohme Corporation | $1,080.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803325 | CMS |
| Merck Sharp & Dohme Corporation | $2,220.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803571 | CMS |
| Merck Sharp & Dohme Corporation | $2,700.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803697 | CMS |
| Merck Sharp & Dohme Corporation | $60.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803703 | CMS |
| Merck Sharp & Dohme Corporation | $300.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803859 | CMS |
| Merck Sharp & Dohme Corporation | $300.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803861 | CMS |
| Merck Sharp & Dohme Corporation | $300.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747803933 | CMS |
| Merck Sharp & Dohme Corporation | $375.00 | 08/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747804013 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $109,709.00 | 22 |
| PY2025 | Principal investigator | $356,635.00 | 23 |
| PY2024 | Recipient | $27,595.00 | 5 |
| PY2024 | Principal investigator | $264,512.51 | 20 |
| PY2023 | Recipient | $105,775.00 | 6 |
| PY2023 | Principal investigator | $869,247.57 | 21 |
| PY2022 | Recipient | $300.00 | 2 |
| PY2022 | Principal investigator | $309,616.28 | 15 |
| PY2021 | Principal investigator | $260,008.17 | 24 |
| PY2020 | Principal investigator | $174,709.37 | 23 |
| PY2019 | Recipient | $6,280.00 | 1 |
| PY2019 | Principal investigator | $159,155.89 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
45 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novartis Pharma AG | $540.00 | 12/23/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248109001 |
| Principal investigator 1 | Novartis Pharma AG | $180.00 | 11/18/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108991 |
| Principal investigator 1 | Novartis Pharma AG | $1,015.00 | 10/21/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108983 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $5,512.00 | 10/03/2025 | Covered Recipient Physician | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1236002109 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $12,240.00 | 10/03/2025 | Covered Recipient Physician | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1236002117 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $150.00 | 10/03/2025 | Covered Recipient Physician | A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment | No dispute reported | 06/30/2026 | 1236002119 |
| Principal investigator 1 | Novartis Pharma AG | $835.00 | 09/16/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108987 |
| Principal investigator 1 | Novartis Pharma AG | $705.00 | 09/02/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108999 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $775.00 | 08/08/2025 | Covered Recipient Physician | A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1236002097 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $9,150.00 | 08/08/2025 | Covered Recipient Physician | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1236002115 |
| Principal investigator 1 | AstraZeneca UK Limited | $9,915.00 | 08/07/2025 | Non-covered Recipient Entity GI REVIEWERS LLC | a phase third,randomized,double blind,placebo controlled,multi centre,global study of volrustomig in women with high risk locally advanced cervical cancer who have not progressed following platinum based,concurrent chemoradiation therapy evolve cervical | No dispute reported | 06/30/2026 | 1185541810 |
| Recipient | GlaxoSmithKline, LLC. | $240.00 | 08/07/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136059 |
| Principal investigator 1 | Novartis Pharma AG | $120.00 | 08/05/2025 | Non-covered Recipient Entity BOSTON IMAGING CORE LAB | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108975 |
| Principal investigator 1 | Novartis Pharma AG | $1,880.00 | 07/15/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108995 |
| Recipient | GlaxoSmithKline, LLC. | $420.00 | 07/08/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136054 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $7,930.00 | 07/03/2025 | Covered Recipient Physician | A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer | No dispute reported | 06/30/2026 | 1236002103 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $329.00 | 07/03/2025 | Covered Recipient Physician | A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigators Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy | No dispute reported | 06/30/2026 | 1236002113 |
| Principal investigator 1 | Novartis Pharma AG | $1,580.00 | 07/01/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108993 |
| Recipient | GlaxoSmithKline, LLC. | $3,660.00 | 06/19/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136098 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,020.00 | 05/27/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185541804 |
| Principal investigator 1 | Novartis Pharma AG | $1,555.00 | 05/27/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108989 |
| Principal investigator 1 | AstraZeneca UK Limited | $2,690.00 | 05/15/2025 | Non-covered Recipient Entity GI REVIEWERS LLC | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185541812 |
| Principal investigator 1 | AstraZeneca UK Limited | $130.00 | 05/13/2025 | Non-covered Recipient Entity BOSTON IMAGING CORE LAB | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185541806 |
| Principal investigator 1 | Novartis Pharma AG | $120.00 | 05/13/2025 | Non-covered Recipient Entity BOSTON IMAGING CORE LAB | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108981 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $170.00 | 05/05/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1236002107 |
| Recipient | GlaxoSmithKline, LLC. | $6,540.00 | 04/10/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136075 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $75.00 | 04/03/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1236002099 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $4,052.00 | 04/03/2025 | Covered Recipient Physician | A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigators Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1236002105 |
| Recipient | GlaxoSmithKline, LLC. | $1,860.00 | 04/03/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136080 |
| Principal investigator 1 | Novartis Pharma AG | $205.00 | 03/27/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108997 |
| Principal investigator 1 | Novartis Pharma AG | $240.00 | 03/11/2025 | Non-covered Recipient Entity BOSTON IMAGING CORE LAB | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108979 |
| Recipient | Ipsen Innovation | $75.00 | 03/06/2025 | Covered Recipient Physician | A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment | No dispute reported | 06/30/2026 | 1184302761 |
| Principal investigator 1 | Novartis Pharma AG | $115.00 | 02/25/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248109003 |
| Principal investigator 1 | Novartis Pharma AG | $240.00 | 02/11/2025 | Non-covered Recipient Entity BOSTON IMAGING CORE LAB | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108977 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $48,716.00 | 02/06/2025 | Covered Recipient Physician | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1236002093 |
| Recipient | GlaxoSmithKline, LLC. | $720.00 | 02/06/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136065 |
| Principal investigator 1 | AstraZeneca UK Limited | $18,270.00 | 01/21/2025 | Non-covered Recipient Entity REMEDIUM IMAGING LLC | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1185541808 |
| Principal investigator 1 | Amgen Inc. | $18,250.00 | 01/14/2025 | Non-covered Recipient Entity GI REVIEWERS LLC | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1246641835 |
| Principal investigator 2 | E.R. Squibb & Sons, L.L.C. | $176,772.50 | 01/14/2025 | Non-covered Recipient Entity GI Reviewers | Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy | No dispute reported | 06/30/2026 | 1235997097 |
| Principal investigator 2 | E.R. Squibb & Sons, L.L.C. | $102,887.50 | 01/09/2025 | Non-covered Recipient Entity GI Reviewers | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1235997099 |
| Recipient | GlaxoSmithKline, LLC. | $3,780.00 | 01/09/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192136086 |
| Principal investigator 1 | AstraZeneca UK Limited | $15,370.00 | 01/07/2025 | Non-covered Recipient Entity BOSTON IMAGING CORE LAB | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185541800 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $1,440.00 | 01/03/2025 | Covered Recipient Physician | A Phase 1 Firstinhuman Study of BMS986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors | No dispute reported | 06/30/2026 | 1236002095 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $605.00 | 01/03/2025 | Covered Recipient Physician | A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer | No dispute reported | 06/30/2026 | 1236002101 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $1,270.00 | 01/03/2025 | Covered Recipient Physician | A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors | No dispute reported | 06/30/2026 | 1236002111 |